Dyax Corp. Company Profile (NASDAQ:DYAX)

About Dyax Corp. (NASDAQ:DYAX)

Dyax Corp. logoDyax Corp is a biopharmaceutical company. The Company is focused on Hereditary Angioedema (HAE) and other Plasma-Kallikrein-Mediated (PKM) Disorders, and licensing and funded research portfolio. The Company develops and commercializes treatments for hereditary angioedema. The Company discovered and developed KALBITOR, a plasma kallikrein inhibitor, and is selling it in the United States for the treatment of acute attacks of HAE. Additionally, it discovered and is developing DX-2930, a human monoclonal antibody inhibitor of plasma kallikrein. It also developed a biomarker assay that detects the activation of plasma kallikrein in patient blood. The Company has a portfolio of product candidates being developed by licensees using its phage display technology. This portfolio includes one approved product, CYRAMZA (ramucirumab), which is marketed by Eli Lilly and Company (Lilly), and multiple product candidates in various stages of clinical development.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DYAX
  • CUSIP: 26746E10
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $37.73
  • 200 Day Moving Avg: $29.05
  • 52 Week Range: $14.06 - $38.56
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -274.36
  • P/E Growth: 0.00
Misc:
  • Average Volume: 3.62 million shs.
 

Frequently Asked Questions for Dyax Corp. (NASDAQ:DYAX)

What is Dyax Corp.'s stock symbol?

Dyax Corp. trades on the NASDAQ under the ticker symbol "DYAX."

How were Dyax Corp.'s earnings last quarter?

Dyax Corp. (NASDAQ:DYAX) posted its quarterly earnings results on Wednesday, October, 28th. The company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $24.70 million for the quarter, compared to the consensus estimate of $24.96 million. The company's revenue for the quarter was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.01) EPS. View Dyax Corp.'s Earnings History.

Who are some of Dyax Corp.'s key competitors?

How do I buy Dyax Corp. stock?

Shares of Dyax Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dyax Corp. stock cost?

One share of Dyax Corp. stock can currently be purchased for approximately $38.41.

Analyst Ratings

Consensus Ratings for Dyax Corp. (NASDAQ:DYAX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Dyax Corp. (NASDAQ:DYAX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/7/2015Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
11/9/2015Leerink SwannDowngradeOutperform -> Market Perform$37.00N/AView Rating Details
11/5/2015Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
11/2/2015Jefferies Group LLCDowngradeBuy -> Hold$37.00N/AView Rating Details
11/2/2015WedbushDowngradeOutperform -> NeutralN/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Dyax Corp. (NASDAQ:DYAX)
Earnings by Quarter for Dyax Corp. (NASDAQ:DYAX)
Earnings History by Quarter for Dyax Corp. (NASDAQ:DYAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/28/2015Q315($0.08)($0.08)$24.96 million$24.70 millionViewN/AView Earnings Details
7/29/2015Q215($0.04)($0.06)$23.40 million$264.00 millionViewListenView Earnings Details
4/29/2015Q115($0.05)($0.05)$21.79 million$20.40 millionViewN/AView Earnings Details
2/24/2015Q414($0.04)($0.02)$19.90 million$26.00 millionViewN/AView Earnings Details
10/28/2014Q314($0.06)($0.01)$15.70 million$22.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.05)($0.02)$14.13 million$19.59 millionViewN/AView Earnings Details
4/30/2014Q1 2014($0.05)($0.05)$13.65 million$14.12 millionViewN/AView Earnings Details
2/28/2014Q413($0.04)($0.02)$15.84 million$16.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dyax Corp. (NASDAQ:DYAX)
Current Year EPS Consensus Estimate: $-0.26 EPS
Next Year EPS Consensus Estimate: $-0.14 EPS

Dividends

Dividend History for Dyax Corp. (NASDAQ:DYAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dyax Corp. (NASDAQ:DYAX)
Insider Trades by Quarter for Dyax Corp. (NASDAQ:DYAX)
Institutional Ownership by Quarter for Dyax Corp. (NASDAQ:DYAX)
Insider Trades by Quarter for Dyax Corp. (NASDAQ:DYAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/10/2015Thomas L KempnerDirectorSell6,000$22.47$134,820.00View SEC Filing  
8/28/2015Thomas L KempnerDirectorSell17,947$23.83$427,677.01View SEC Filing  
8/18/2015Thomas L KempnerDirectorSell18,035$23.83$429,774.05View SEC Filing  
8/13/2015Thomas L KempnerDirectorSell4,848$23.81$115,430.88View SEC Filing  
7/20/2015Henry E BlairDirectorSell50,000$27.05$1,352,500.00View SEC Filing  
6/8/2015David J MclachlanDirectorSell75,000$25.63$1,922,250.00View SEC Filing  
3/6/2015Andrew D AsheEVPSell2,400$15.50$37,200.00View SEC Filing  
3/5/2015Burt A AdelmanCMOSell9,375$15.66$146,812.50View SEC Filing  
3/5/2015George V MigauskyCFOSell5,000$15.86$79,300.00View SEC Filing  
3/5/2015Gustav ChristensenCEOSell6,250$15.86$99,125.00View SEC Filing  
2/26/2015Andrew D AsheEVPSell1,500$15.34$23,010.00View SEC Filing  
1/2/2015Burt A AdelmanCMOSell75,000$14.05$1,053,750.00View SEC Filing  
12/5/2014Thomas L KempnerDirectorSell14,764$13.79$203,595.56View SEC Filing  
11/21/2014Thomas L KempnerDirectorSell100,000$13.20$1,320,000.00View SEC Filing  
9/12/2014Thomas L KempnerDirectorSell12,400$11.00$136,400.00View SEC Filing  
8/26/2014Thomas L KempnerDirectorSell37,000$10.39$384,430.00View SEC Filing  
8/19/2014Thomas L KempnerDirectorSell113,755$9.67$1,100,010.85View SEC Filing  
8/7/2014Thomas L KempnerDirectorSell33,190$9.25$307,007.50View SEC Filing  
6/13/2014George V MigauskyCFOSell16,000$8.26$132,160.00View SEC Filing  
3/5/2014Henry BlairDirectorSell150,000$10.46$1,569,000.00View SEC Filing  
3/3/2014Andrew AsheEVPSell30,000$10.00$300,000.00View SEC Filing  
3/3/2014Burt AdelmanCMOSell55,000$9.68$532,400.00View SEC Filing  
2/26/2014Andrew AsheVPSell2,723$10.10$27,502.30View SEC Filing  
12/5/2013Thomas KempnerDirectorSell400,000$8.37$3,348,000.00View SEC Filing  
8/13/2013Andrew AsheVPSell32,500$4.30$139,750.00View SEC Filing  
5/16/2013Marc D KozinDirectorBuy22,971$2.46$56,508.66View SEC Filing  
2/25/2013George V MigauskyCFOSell4,275$3.28$14,022.00View SEC Filing  
2/25/2013Ivana MagovcevicCOOSell4,015$3.24$13,008.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dyax Corp. (NASDAQ:DYAX)
Latest Headlines for Dyax Corp. (NASDAQ:DYAX)
Source:
DateHeadline
businesswire.com logoOcular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer
www.businesswire.com - April 7 at 9:32 AM
finance.yahoo.com logoIs Vista Outdoor Inc (VSTO) A Good Stock To Buy?
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoDo Hedge Funds Love Dyax Corp. (DYAX)?
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoHere's Why Dyax Corp.'s Shares Jumped Today
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoStrength Seen in Dyax Corp (DYAX): Stock Rises 12.2%
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoThe SPDR S&P Biotech ETF Lingers in the Red as of December 3
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoWhy Dyax Corp Rocketed 22% Higher in November
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logo5 Top Performing Stocks of the Top ETF of 2015
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: ALPS Medical Breakthroughs ETF, Anacor Pharmaceuticals, Dyax, Ultragenyx Pharmaceutical and ImmunoGen
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logo3 Stocks Making New 52-Week Highs
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoTechnical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and Baxalta
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoHere Are The Most Notable Insider Transactions Hitting The Market
finance.yahoo.com - April 7 at 9:32 AM
finance.yahoo.com logoShire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary ... - Yahoo Finance
finance.yahoo.com - March 24 at 10:09 PM
prnewswire.com logoShire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary ... - PR Newswire (press release)
www.prnewswire.com - March 22 at 10:01 PM
prnewswire.com logoShire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in ... - PR Newswire (press release)
www.prnewswire.com - February 18 at 9:39 AM
finance.yahoo.com logoShire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in ... - Yahoo Finance
finance.yahoo.com - February 16 at 3:37 PM
marketwatch.com logoWho is the top fee payer to banks in Europe?
www.marketwatch.com - January 27 at 6:27 PM
finance.yahoo.com logoTop 6 Vendors in the Global Myasthenia Gravis Drugs Market from 2017 to 2021: Technavio - Yahoo Finance
finance.yahoo.com - January 22 at 4:47 PM
streetinsider.com logoXOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and ... - StreetInsider.com
www.streetinsider.com - December 21 at 10:40 PM
streetinsider.com logoXOMA (XOMA) Sells Two Royalty Streams, Reduces Headcount and Names New CEO
www.streetinsider.com - December 21 at 5:38 PM

Social

Chart

Dyax Corp. (DYAX) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff